Weight loss jabs such as Ozempic and Mounjaro are associated with a phenomenon known as 'Ozempic butt,' but a new drug may offer a solution. Despite the popularity of these medications—1.6 million Brits used GLP-1s last year—side effects like nausea and vision changes are common. Recently, 'Ozempic butt' has emerged as another concern.
What Is Ozempic Butt?
'Ozempic butt' refers to the loss of volume or flattening of the buttocks following significant weight loss while on medications like Wegovy or Mounjaro, explains Dr. Suzanne Wylie, GP and medical adviser for IQdoctor. This is not a direct drug side effect but a result of rapid weight loss, which reduces both fat and muscle mass, altering body shape.
The American Society of Plastic Surgeons reports a 'noticeable uptick' in procedures to restore shape to the lower body. However, muscle loss affects the entire body, with studies indicating that 25 to 40% of weight loss from these drugs is lean body mass, including muscle.
Why Muscle Loss Matters
Dr. Suzanne emphasizes that muscle is crucial for strength, mobility, and overall health. 'The best way to preserve muscle while losing fat is through regular resistance exercise, such as weight training, squats, and lunges, along with adequate protein intake,' she advises. The NHS recommends muscle-strengthening activities at least twice a week, including stair climbing, chair exercises, or heavy gardening.
Consult your GP or an exercise specialist before starting a new fitness regimen.
Could a New Drug Help?
Apitegromab, an experimental drug administered intravenously, blocks myostatin—a protein involved in muscle breakdown. In a 24-week trial of 102 participants (mostly women), those receiving apitegromab plus tirzepatide lost 1.63kg of lean mass, compared to 3.5kg in the placebo group. Researchers call the findings 'promising' but stress the need for more safety and long-term data.
Apitegromab is also being studied for conditions like spinal muscular atrophy.
